LADASTEN® INSTRUCTIONS FOR USE

(translation from Russian by RUPharma.com)

Registration number: 010 257-LSR / 08-191208
The trade name of the drug: Ladasten®
Chemical management name: N- (2-adamantyl) -N- (2-n-bromophenyl) amine.
INN or the name of the grouping: bromantane.
Dosage Form: Tablet.

Structure
Each tablet contains:
Active ingredient: bromantane (adamantilfenilamin) - 0.05 g and 0.10 g
Other ingredients: potato starch, microcrystalline cellulose, magnesium stearate.

Description
Tablets white or white cream color shade, round shape and beveled.

Pharmacodynamics
Ladasten® is adamantane derivative, a positive impact on the performance of physical and mental performance. The spectrum drug action combination are activated by anxiolytic, immunostimulant actions and elements actoprotective activity. There are no Ladasten® muscle relaxant properties, the drug does not cause addiction. In its application, unlike a typical action of psychostimulants, practically hyperstimulation conditions develop, and aftereffects of functional exhaustion of the body.
The therapeutic effect in patients with Ladasten® asthenia and anxiety-asthenic disorders manifested from the first day of its application in the form of a distinct reduction asthenic symptoms, indicators of emotional stress. Medication helps to restore the activity and increase endurance.
The mechanism of Ladasten® action is associated with increased release of dopamine from presynaptic terminals, it reuptake blockade and increased biosynthesis caused by expression of tyrosine-hydroxylase gene as well as its modulatory effect on the GABA-benzodiazepine receptor complex reducing benzodiazepine reception, which develop at stress. Ladasten® enhances GABAergic mediation, reducing the expression of the gene controlling the synthesis of GABA transporter carrying out the reuptake of the neurotransmitter.
Ladasten® is toxic at more than 100 times greater than the effective dose (LD50 in rats is greater than 10,000 mg / kg,).

Pharmacokinetics
The time to reach maximum concentration (Tmax) is about 2-4 hours, the maximum concentration (Cmax) of 363.3 ng / mL, the drug elimination half-life (T1 / 2) - 11.21 hours.

Usage
Asthenic conditions of various origins, including in somatic diseases and after infectious diseases. Neurasthenia.

Contraindications
Pregnancy, lactation, children under 18 years of age, individual intolerance of the drug.

Dosing and Administration
Taken orally, regardless of meals. The optimal single dose - 50-100 mg; daily recommended dose - 100-200 mg, distributed over 2 intakes during the day. The drug should not be used after 16:00 of the day to prevent insomnia. The duration of a course of the drug is 2-4 weeks.

Side effects
Symptoms may include the excessive activation and sleep disorders that do not require discontinuation of the drug, it is advisable to decrease the dose. With increased individual sensitivity to the drug may develop allergic reactions.

Overdose
Large overdose may develop sedation.
Treatment: non-specific detoxification therapy.

Interaction with other drugs
Ladasten® reduces the hypnotic effect of thiopental sodium, it does not weaken the anxiolytic effects of benzodiazepines.

Product form
Tablets of 50 mg. 50 tablets in blisters of polyvinyl chloride film and aluminum foil printed patent.
2 blisters with instruction on use in the stack of cardboard.

Storage conditions
In a dry, dark place at a temperature no higher than 25°C.
Keep out of the reach of children.

Shelf life
2 years. Do not use after expiration date printed on the package.

Manufacturer
ZAO "Pharmaceutical Company" Lecko "
601125, Vladimir region., Petushki district, pos. Volginsky,
tel / fax (49243) 71-5-52.

Consumer complaints sent to the address of JSC "Pharmaceutical Company "Lecko", 601125, Vladimir region., Petushki district, pos. Volginsky, tel / fax (49243) 71-5-52.